NDAINTRAVENOUSSOLUTION
Approved
Apr 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
MOXIFLOXACIN HYDROCHLORIDE (moxifloxacin hydrochloride) by Fresenius Kabi is [see microbiology ()]. First approved in 2015.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Moxifloxacin hydrochloride is a broad-spectrum fluoroquinolone antibiotic administered intravenously for bacterial infections. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication. The IV formulation enables rapid systemic delivery for serious infections requiring hospitalization.
Peak
Product is at peak commercial maturity under Fresenius Kabi ownership with established hospital formulary presence; team focus likely on volume optimization and market defense.
Mechanism of Action
[see Microbiology ()].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery
Started Jan 2024
102 enrolled
Post Operative Endophthalmitis
Career Relevance
Working on moxifloxacin IV positions you in acute care/hospital sales and infectious disease marketing, a stable segment with entrenched customer relationships. Career value lies in formulary management, payer negotiations, and institutional contracting expertise rather than new product innovation.
Hospital Account Manager
Worked on MOXIFLOXACIN HYDROCHLORIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.